Survival of GEJ and gastric adenocarcinoma patients admitted at Imam Khomeini and Aram oncology clinic and treated with preoperative EOX chemotherapy
gastric cancer survival
,
Abstract
Abstract Objective: We aimed to investigate safety and efficacy of preoperative chemotherapy using EOX regime in patients with locally advanced gastric and GEJ cancer who were admitted at Imam-Khomeini Oncology clinic and Aram clinic. Method: We performed a mix-cohort study in 51 gastric cancer patients. In the beginning, we performed contrast thorax and abdominal CT scan or ECO cardiograph to determine cancer staging. After that, each patient received 3-weeks EOX regime in 6 cycle. After each three cycles follow-up CT scan was performed to assess any possible progression. Response to the treatment, Overall survival, and Progression-Free Survival were the main outcomes that we evaluated in the current study. We used Kaplan-Meier approach and Cox regression to address survival rate and its prognostic factors. Results: Overall, 72.5% percent were male and mean age of study participants was 57.6. Complete response rate was observed in 11.1%, while 51.1% showed partial response. Median of overall survival and Progression-Free Survival was estimated 35.0 and 28.0 month, respectively. The 5-year overall survival was 74.2% and for PFS it was estimated at 57.7%. Conclusion: Preoperative chemotherapy using EOX regime could increase survival rate among patients with gastric and GEJ cancer.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
2. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Internal medicine. 2008;47(12):1077-83.
3. Balakrishnan M, George R, Sharma A, Graham DY. Changing trends in stomach cancer throughout the world. Current gastroenterology reports. 2017;19(8):36.
4. Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. 2009.
5. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26-38. PubMed PMID: 30944675. Epub 11/28. eng.
6. Veisani Y, Delpisheh A. Survival rate of gastric cancer in Iran; a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2016 Spring;9(2):78-86. PubMed PMID: 27099666. eng.
7. Das M. Neoadjuvant chemotherapy: survival benefit in gastric cancer. The Lancet Oncology. 2017;18(6):e307.
8. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon J-P, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. Jama. 2010;303(17):1729-37.
9. Chen W, Shen J, Pan T, Hu W, Jiang Z, Yuan X, et al. FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer. Experimental and therapeutic medicine. 2014;7(2):461-7.
10. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20(7):1635-49. PubMed PMID: 24587643. eng.
11. Ostwal V, Sahu A, Ramaswamy A, Sirohi B, Bose S, Talreja V, et al. Perioperative epirubicin, oxaliplatin, and capecitabine chemotherapy in locally advanced gastric cancer: Safety and feasibility in an interim survival analysis. Journal of Gastric Cancer. 2017;17(1):21-32.
12. Chen W, Shen J, Pan T, Hu W, Jiang Z, Yuan X, et al. FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer. Exp Ther Med. 2014 Feb;7(2):461-7. PubMed PMID: 24396426. Pubmed Central PMCID: PMC3881068. Epub 2014/01/08. eng.
13. Coleman MP, Quaresma M, Berrino F, Lutz J-M, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). The lancet oncology. 2008;9(8):730-56.
14. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? Jama. 2000 Jun 14;283(22):2975-8. PubMed PMID: 10865276. Epub 2000/06/24. eng.
15. Mongan AM, Kalachand R, King S, O’Farrell N, Power D, Ravi N, et al. Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery. Irish Journal of Medical Science (1971-). 2015;184(2):417-23.
16. Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World Journal of Gastroenterology: WJG. 2015;21(24):7343.
17. Pluschnig U, Schoppmann SF, Preusser M, Datler P, Asari R, Ba-Ssalamah A, et al. Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. Anticancer research. 2013 Mar;33(3):1035-9. PubMed PMID: 23482778. Epub 2013/03/14. eng.
18. Pani C, Dubashi B, Cyriac S, Dhanraj K, Verma S, Sistla S. First Line Treatment for Advanced Gastroesophageal Cancer: Capecitabine Plus Oxaliplatin (CAPOX) versus Epirubicin, Oxaliplatin Plus Capecitabine (EOX). Austin J Cancer Clin Res. 2017;4(1):1073.
19. Wang Y, Zhuang RY, Yu YY, Yu S, Hou J, Ji Y, et al. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget. 2016 Nov 15;7(46):76298-307. PubMed PMID: 27602586. Pubmed Central PMCID: PMC5342815. Epub 2016/09/08. eng.
20. Bozkaya Y, Özdemir NY, Yazıcı O, Demirci NS, Kurtipek A, Erdem GU, et al. A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer. Asian Pacific journal of cancer prevention : APJCP. 2018 Jan 27;19(1):283-90. PubMed PMID: 29374414. Pubmed Central PMCID: PMC5844632. Epub 2018/01/28. eng.
21. Verdecchia A, Corazziari I, Gatta G, Lisi D, Faivre J, Forman D. Explaining gastric cancer survival differences among European countries. International journal of cancer. 2004;109(5):737-41.
22. Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Annals of surgery. 1998;228(4):449.
2. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Internal medicine. 2008;47(12):1077-83.
3. Balakrishnan M, George R, Sharma A, Graham DY. Changing trends in stomach cancer throughout the world. Current gastroenterology reports. 2017;19(8):36.
4. Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. 2009.
5. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26-38. PubMed PMID: 30944675. Epub 11/28. eng.
6. Veisani Y, Delpisheh A. Survival rate of gastric cancer in Iran; a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2016 Spring;9(2):78-86. PubMed PMID: 27099666. eng.
7. Das M. Neoadjuvant chemotherapy: survival benefit in gastric cancer. The Lancet Oncology. 2017;18(6):e307.
8. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon J-P, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. Jama. 2010;303(17):1729-37.
9. Chen W, Shen J, Pan T, Hu W, Jiang Z, Yuan X, et al. FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer. Experimental and therapeutic medicine. 2014;7(2):461-7.
10. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20(7):1635-49. PubMed PMID: 24587643. eng.
11. Ostwal V, Sahu A, Ramaswamy A, Sirohi B, Bose S, Talreja V, et al. Perioperative epirubicin, oxaliplatin, and capecitabine chemotherapy in locally advanced gastric cancer: Safety and feasibility in an interim survival analysis. Journal of Gastric Cancer. 2017;17(1):21-32.
12. Chen W, Shen J, Pan T, Hu W, Jiang Z, Yuan X, et al. FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer. Exp Ther Med. 2014 Feb;7(2):461-7. PubMed PMID: 24396426. Pubmed Central PMCID: PMC3881068. Epub 2014/01/08. eng.
13. Coleman MP, Quaresma M, Berrino F, Lutz J-M, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). The lancet oncology. 2008;9(8):730-56.
14. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? Jama. 2000 Jun 14;283(22):2975-8. PubMed PMID: 10865276. Epub 2000/06/24. eng.
15. Mongan AM, Kalachand R, King S, O’Farrell N, Power D, Ravi N, et al. Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery. Irish Journal of Medical Science (1971-). 2015;184(2):417-23.
16. Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World Journal of Gastroenterology: WJG. 2015;21(24):7343.
17. Pluschnig U, Schoppmann SF, Preusser M, Datler P, Asari R, Ba-Ssalamah A, et al. Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. Anticancer research. 2013 Mar;33(3):1035-9. PubMed PMID: 23482778. Epub 2013/03/14. eng.
18. Pani C, Dubashi B, Cyriac S, Dhanraj K, Verma S, Sistla S. First Line Treatment for Advanced Gastroesophageal Cancer: Capecitabine Plus Oxaliplatin (CAPOX) versus Epirubicin, Oxaliplatin Plus Capecitabine (EOX). Austin J Cancer Clin Res. 2017;4(1):1073.
19. Wang Y, Zhuang RY, Yu YY, Yu S, Hou J, Ji Y, et al. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget. 2016 Nov 15;7(46):76298-307. PubMed PMID: 27602586. Pubmed Central PMCID: PMC5342815. Epub 2016/09/08. eng.
20. Bozkaya Y, Özdemir NY, Yazıcı O, Demirci NS, Kurtipek A, Erdem GU, et al. A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer. Asian Pacific journal of cancer prevention : APJCP. 2018 Jan 27;19(1):283-90. PubMed PMID: 29374414. Pubmed Central PMCID: PMC5844632. Epub 2018/01/28. eng.
21. Verdecchia A, Corazziari I, Gatta G, Lisi D, Faivre J, Forman D. Explaining gastric cancer survival differences among European countries. International journal of cancer. 2004;109(5):737-41.
22. Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Annals of surgery. 1998;228(4):449.
| Files | ||
| Issue | Vol 14 No 2 (2022) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/bccr.v14i2.14375 | |
| Keywords | ||
| Gastric cancer Progression-Free Survival Neo-adjuvant chemotherapy preoperative treatment. | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Farahat A, Emami A, Safaei Nodehi SR, Roudini K, Shahi F. Survival of GEJ and gastric adenocarcinoma patients admitted at Imam Khomeini and Aram oncology clinic and treated with preoperative EOX chemotherapy. Basic Clin Cancer Res. 2023;14(2):78-86.
